Drug Name
EligibleStudy sitesMore information
Anifrolumab (JASMINE)
Ages 18-75 with DM or PM185 sites worldwideMore details »
AstraZeneca »
877-240-9479
NCT06455449
Brepocitinib (VALOR)
Adults with dermatomyositis (DM)
(currently not recruiting)More details »
Priovant
212-634-9743
NCT05437263
CABA-201 (CAR T cell therapy)
Ages 6-75 with DM, ASyS, NM11 locations in the US,
4 in UK,
additional sites
expected soon		More details »
Cabaletta Bio »
NCT06154252
CD-19-Targeted (CAR T cell therapy)
Adults with refractory DM, PM, NM54 sites in US and EuropeMore details »
Bristol Myers Squibb »
855-907-3286
NCT05869955
Daxdilimab
Adults with DM or ASyS(currently not recruiting)More details »
Amgen
866-479-6742
NCT05669014
Dazukibart
Adults with active DM or PM126 sites worldwideMore details »
Pfizer »
800-718-1021
NCT05895786
Efgartigimod (ALKIVIA)
Adults with IIM201 sites worldwideMore details »
argenx
857-350-4834
NCT05523167
Empasiprubart (Empacific)
Adults with DM14 sites in US
6 sites in Europe		More details »
argenx
857-350-4834
NCT06284954
Enpatoran (NEPTUNIA)
Adults with DM or PM13 sites in US
18 sites abroad		More details »
EMD Serono
888-275-7376
NCT05650567
GLPG3667 (not yet named)
Adults with dermatomyositis (DM)59 sites worldwideMore details »
Galapagos NV
321-534-2900
NCT05695950
Nintedanib (MINT)
Adults with ILD and myositis(currently not recruiting)More details »
MINTcc@pitt.edu
412-648-9989
NCT05799755
Nipocalimab (SPIREA)
Adults with IIM(currently not recruiting)More details »
J&J Innovative Medicine
844-434-4210
NCT05379634
NKX019 (allogeneic CAR NK cells targeting CD19)
Ages 18-65 with dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), or anti-synthetase syndrome (ASyS)20 sites in US
2 sites in AUS		More details »
Nkarta, Inc.
clinicaltrials@nkartatx.com
NCT06733935
Rapcabtagene Autoleucel (CAR T cell therapy)
Adults with DM, NM, ASyS1 site in US
9 sites abroad		More details »
Novartis
1-888-669-6682
NCT06665256
RAY121 (RAINBOW Trial)
Ages 18-75 with dermatomyositis (DM) or immune-mediated necrotizing myopathy (IMNM)7 sites in US
5 sites in CAN
~70 sites abroad, additional sites expected late 2025		More details »
Chugai Pharmaceuticals Co., Ltd
clinical-trials@chugai-pharm.co.jp
NCT06371417
Sirolimus
Adults with inclusion body myositis (IBM)(currently not recruiting)More details »
913-945-9926
NCT04789070
Ulviprubart (ABC008)
Adults with inclusion body myositis (IBM)(currently not recruiting)More details »
Abcuro/Syneos
617-865-5079
NCT05721573